AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...
If the company is forced to offload even 100,000 of its 649,870 coins to meet obligations, it could trigger a systemic ...
The significance is structural: IBM is not eliminating “underperforming units” but dismantling entire human layers in favor ...
L ate in Claire-Louise Bennett’s novel Big Kiss, Bye-Bye, the unnamed protagonist goes to Montevideo to participate in a ‘panel discussion about violent scenes from movies’. She had hesitated to ...
By David Swanson, World BEYOND War Ah, those were the days. The UN had been blocked by a worldwide popular movement from ...
Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...
Recursion Pharmaceuticals Inc. (RXRX) reported its third-quarter 2025 earnings, revealing a mixed performance with an EPS of -$0.36, slightly surpassing the forecast of -$0.37. However, the company ...
Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.
The latest announcement is out from Recursion Pharmaceuticals ( ($RXRX) ). On November 26, 2025, Recursion Pharmaceuticals filed a prospectus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback